1. Home
  2. GLUE vs VSTA Comparison

GLUE vs VSTA Comparison

Compare GLUE & VSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • VSTA
  • Stock Information
  • Founded
  • GLUE 2019
  • VSTA 1966
  • Country
  • GLUE United States
  • VSTA Brazil
  • Employees
  • GLUE N/A
  • VSTA N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • VSTA Other Consumer Services
  • Sector
  • GLUE Health Care
  • VSTA Real Estate
  • Exchange
  • GLUE Nasdaq
  • VSTA Nasdaq
  • Market Cap
  • GLUE 351.2M
  • VSTA 332.9M
  • IPO Year
  • GLUE 2021
  • VSTA 2020
  • Fundamental
  • Price
  • GLUE $4.80
  • VSTA $4.28
  • Analyst Decision
  • GLUE Buy
  • VSTA Sell
  • Analyst Count
  • GLUE 2
  • VSTA 1
  • Target Price
  • GLUE $13.50
  • VSTA N/A
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • VSTA 14.1K
  • Earning Date
  • GLUE 08-07-2025
  • VSTA 08-06-2025
  • Dividend Yield
  • GLUE N/A
  • VSTA N/A
  • EPS Growth
  • GLUE N/A
  • VSTA N/A
  • EPS
  • GLUE 0.29
  • VSTA 1.09
  • Revenue
  • GLUE $177,986,000.00
  • VSTA $313,466,268.00
  • Revenue This Year
  • GLUE $83.76
  • VSTA $12.29
  • Revenue Next Year
  • GLUE N/A
  • VSTA $11.91
  • P/E Ratio
  • GLUE $16.32
  • VSTA $3.94
  • Revenue Growth
  • GLUE 2990.57
  • VSTA 8.99
  • 52 Week Low
  • GLUE $3.50
  • VSTA $1.60
  • 52 Week High
  • GLUE $12.40
  • VSTA $5.49
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • VSTA 56.69
  • Support Level
  • GLUE $4.54
  • VSTA $3.78
  • Resistance Level
  • GLUE $4.93
  • VSTA $4.38
  • Average True Range (ATR)
  • GLUE 0.21
  • VSTA 0.18
  • MACD
  • GLUE 0.06
  • VSTA 0.00
  • Stochastic Oscillator
  • GLUE 81.43
  • VSTA 83.33

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About VSTA Vasta Platform Limited

Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.

Share on Social Networks: